In today’s briefing:
- Huadong Medicine Co Ltd (000963.CH) – The Medical Cosmetology Business Is the Key Breakthrough Point
- Breaking Growth Short Candidates: Quanterix, Insulet, Inari Med, MercadoLibre
- HealthCare Global: High-End Work Improves Realisations
Huadong Medicine Co Ltd (000963.CH) – The Medical Cosmetology Business Is the Key Breakthrough Point
- Huadong Medicine (000963 CH)’s traditional core businesses are facing great pressure due to VBP and medical insurance negotiation, which is difficult for Huadong to establish its long-term core competitiveness.
- Despite the fierce competition in medical cosmetology industry, the entry of medical cosmetology equipment field is a wise step, helping Huadong form the most complete layout among competitors.
- In terms of whether Huangdong could achieve business transformation successfully, the future performance of medical cosmetology business is the key breakthrough point.
Breaking Growth Short Candidates: Quanterix, Insulet, Inari Med, MercadoLibre
- This model looks for slowing growth, margin declines, sales and/or earnings disappointments, troubling working capital trends, poor estimate trends or lowered guidance, among other characteristics.
- The key judgement is whether a slowdown is temporary or the beginning of a trend. These shorts tend to have high valuations and betas. Multiple compression accelerates the stock’s decline.
- Today we are flagging Quanterix, Insulet, Inari Med, and MercadoLibre
HealthCare Global: High-End Work Improves Realisations
- Healthcare Global Enterprises (HCG) reported revenue Rs 358 Cr grew by 30.7% YoY which is in line with expectations.
- This growth is primarily led by healthy ARPOB (Rs 38,320) that has shown growth of 15.8% YoY and the number of occupied bed days grew by 17% YoY
- We recommend “BUY” with a target price of Rs 330.
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.
Before it’s here, it’s on Smartkarma
